CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets
Cash and cash equivalents	$ 131,496,674	$ 129,609,317
Accounts receivable, net of allowance for doubtful accounts	22,404,534	11,206,244
Inventories	83,676,773	75,679,173
Prepayments and other current assets	6,480,946	5,664,919
Total Current Assets	244,058,927	222,159,653
Property, plant and equipment, net	67,126,063	51,325,177
Intangible assets, net	2,840,550	3,541,582
Land use rights, net	7,038,767	5,818,709
Deposits related to land use rights	16,772,063	14,752,574
Restricted cash and deposit	32,064,962	2,912,145
Equity method investment	11,652,366	10,537,310
Total Assets	381,553,698	311,047,150
Current Liabilities
Short-term bank loans	4,890,000	7,935,000
Accounts payable	4,060,550	2,908,624
Due to related parties	4,208,582	4,081,624
Other payables and accrued expenses	29,625,322	25,423,349
Advance from customers	2,100,906	2,857,420
Income tax payable	5,483,734	4,513,075
Total Current Liabilities	50,369,094	47,719,092
Long-term bank loans	30,000,000	0
Deferred income	2,991,050	2,912,145
Other liabilities	3,468,575	2,996,749
Total Liabilities	86,828,719	53,627,986
Stockholders' Equity
Common stock: par value $0.0001; 100,000,000 shares authorized; 27,046,556 and 26,629,615 shares issued at September 30, 2013 and December 31, 2012, respectively; 25,566,852 and 26,629,615 shares outstanding at September 30, 2013 and December 31, 2012, respectively	2,704	2,663
Additional paid-in capital	68,698,856	62,251,731
Treasury stock, 1,479,704 and nil shares at September 30, 2013 and December 31, 2012, respectively, at cost	(29,594,080)	0
Retained earnings	164,916,809	119,143,000
Accumulated other comprehensive income	20,477,319	14,072,322
Total equity attributable to China Biologic Products, Inc.	224,501,608	195,469,716
Noncontrolling interest	70,223,371	61,949,448
Total Stockholders' Equity	294,724,979	257,419,164
Commitments and contingencies	0	0
Total Liabilities and Stockholders' Equity	$ 381,553,698	$ 311,047,150